Getinge publishes prospectus regarding the rights issue

The prospectus relating to Getinge’s rights issue of MSEK 4,324 has today been approved and registered by the Swedish Financial Supervisory Authority.

The prospectus and application forms for subscription without preferential right can be obtained from Getinge and SEB and are available at Getinge’s website, www.getinge.com and at SEB’s website for prospectuses, www.sebgroup.com/prospectuses.

Advisors

SEB Corporate Finance is financial advisor and Mannheimer Swartling is legal advisor to Getinge in connection with the rights issue.

For more information:

Lars Mattsson, Head of Investor Relations
Phone: +46(0)10 335 00 43
E-mail: lars.mattsson@getinge.com

About Getinge

Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving everyday life for people, today and tomorrow.

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Getinge AB. Any invitation to the persons concerned to subscribe for shares in Getinge is only made through the prospectus which Getinge AB publishes today. 

This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be registered under the United States Securities Act of 1933 (“Securities Act”) or securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, used, pledged, sold, resold, allotted, delivered or transferred, directly or indirectly, into or within the United States, other than pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect Getinge AB’s current view on future events and financial and operational development. Words such as “intend”, “expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.